Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression
J Cancer Res Ther
;
2019 Oct; 15(5): 1282-1287
Article
| IMSEAR
| ID: sea-213524
ABSTRACT
Aim of Study Bevacizumab (BV) is broadly used to treat a number of cancers; however, BV resistance mechanisms and strategies to overcome this resistance are yet to be determined. Materials and Methods:
In this study, we used ovarian xenograft model to evaluate the underlying resistance mechanisms of BV in ovarian cancer treatment.Results:
Our results showed that EphB4 was overexpressed in BV-resistant xenograft models instead of other common receptor tyrosine kinases. In addition, when coadministrated with EphB4 blocker NVP-BHG712, the antitumor effect of BV was significantly enhanced in the resistant model, further confirmed the role of EphB4 in BV-resistant ovarian cancer. These results indicate that NVP-BHG712 reverses EphB4 overexpression-mediated resistance to BV.Conclusion:
These findings represent a guide for the design of future medication strategy and may be useful in guiding the use of BV in combination with NVP-BHG712 in patients with resistance or intolerance ovarian cancer.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Type d'étude:
Étude pronostique
Texte intégral:
J Cancer Res Ther
Thème du journal:
Neoplasms
/
Therapeutics
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS